Company: LGNZZ
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0000886163-25-000025
Chunk: 21

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 21
---
2025.

As of December 31, 2024, our non-employee directors listed in the table above held outstanding stock awards and options, as follows:

| Name                        |     |       | Number of Shares Underlying Outstanding Restricted Stock Units |     |        | Number of Shares Underlying Outstanding Stock Options |
| Jason M. Aryeh              |     | 1,252 |                                                                |     | 37,744 |                                                       |
| Nancy R. Gray, Ph.D.        |     | 1,252 |                                                                |     | 35,146 |                                                       |
| Jason Haas                  |     | 2,252 |                                                                |     | 21,043 |                                                       |
| John W. Kozarich, Ph.D.     |     | 1,252 |                                                                |     | 42,289 |                                                       |
| John L. LaMattina, Ph.D.    |     | 1,252 |                                                                |     | 37,744 |                                                       |
| Stephen L. Sabba, M.D.      |     | 1,252 |                                                                |     | 42,289 |                                                       |
| Martine Zimmermann, PharmD. |     | 2,775 |                                                                |     | 16,789 |                                                       |

### REQUIRED VOTE
Directors will be elected by a plurality of the votes cast. Therefore, the eight director nominees receiving the most “For” votes from the holders of shares present at the meeting or represented by proxy and entitled to vote on the election of directors will be elected. Withholding authority to vote your shares with respect to one or more director nominees will have no effect on the election of those nominees. Absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on the election of directors. Broker non-votes will also have no effect on the election of the nominees. Stockholders are not permitted to cumulate their shares for the purpose of electing directors or otherwise.

### RECOMMENDATION OF THE BOARD OF DIRECTORS
The Board unanimously recommends a vote FOR the nominees listed above under “Business Experience of Director Nominees.”

18

Proposal No. 2

### RATIFICATION OF INDEPENDENT REGISTERED PUBLIC

### ACCOUNTING FIRM
In February 2025, our Audit Committee approved the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025. You are being asked